Obesity Jab Drug Fails To Slow Alzheimer's

Drug shaper Novo Nordisk says semaglutide, nan progressive constituent for nan weight nonaccomplishment jab Wegovy, does not slow Alzheimer's - contempt first hopes that it mightiness thief against dementia.

Researchers began 2 ample tests involving much than 3,800 group aft reports nan medicine was having an effect successful nan existent world.

But nan studies showed nan GLP-1 drug, which is already utilized to negociate type 2 glucosuria and obesity, made nary quality compared to a dummy drug.

The disappointing results are owed to beryllium presented astatine an Alzheimer's illness convention adjacent period and are yet to beryllium published successful a peer-reviewed journal.

Martin Holst Lange, main technological serviceman and executive vice president of investigation and improvement astatine Novo Nordisk, said: "Based connected nan important unmet request successful Alzheimer's illness arsenic good arsenic a number of suggestive information points, we felt we had a work to research semaglutide's potential, contempt a debased likelihood of success.

"While semaglutide did not show efficacy successful slowing nan progression of Alzheimer's disease, nan extended assemblage of grounds supporting semaglutide continues to supply benefits for individuals pinch type 2 diabetes, obesity, and related comorbidities," he said.

Dr Susan Kohlhaas from Alzheimer's Research UK said nan results would travel arsenic a rustle for group affected by Alzheimer's.

The patients who took portion successful nan Evoke tests were aged betwixt 55 and 85 and had mild cognitive impairment aliases mild dementia owed to Alzheimer's disease.

Dementia progression was monitored and measured done tests and interviews.

Treatment pinch semaglutide resulted successful betterment of Alzheimer's disease-related biomarkers, but this did not construe into delaying progression of nan disease.

Dr Kohlhaas said: "These proceedings results are different reminder that Alzheimer's is driven by respective different biologic processes. No azygous attack is apt to beryllium enough.

"The section now needs to attraction connected knowing those processes successful overmuch greater item and processing treatments that tin beryllium utilized together to tackle nan illness from aggregate angles."

She added that nan increasing usage of GLP-1 medicines done backstage prescriptions, mostly for weight loss, offers an opportunity to stitchery amended real-world information connected their longer-term effects.

Fiona Carragher, main argumentation and investigation serviceman astatine Alzheimer's Society, said while it was "very disappointing" that these eagerly awaited results were not what everyone had hoped for, "no proceedings is wasted".

"Every investigation helps america create amended narcotics and creation amended tests successful nan future."

She said location were presently much than 130 Alzheimer's narcotics successful objective tests of which astir 30 are successful late-stage tests - nan last measurement earlier they are considered by regulators.